TSE:CURA

Curaleaf Holdings Inc (CURA.TO)

12.95
+0.02 (0.15%)
as of Aug 7, 2026, 8:00:01 pm Market Open.
119 watching
0
Investor Insights
star iconAug 9, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Curaleaf Holdings Inc (CURA) is currently at the center of significant market speculation surrounding the reclassification of cannabis in the U.S. This potential change is seen as a catalyst for reducing the tax burden on cannabis companies, although predictions about timing remain uncertain and laden with volatility. Experts highlight that CURA and its competitors, such as Trulieve (TRUL), are well-positioned in a growing sector despite the political challenges and restrictive tax regulations that currently govern the industry. Furthermore, many analysts believe that the cannabis sector, including CURA, has improved markedly with cleaner balance sheets and better management, suggesting that value may be overlooked in the broader market. However, this is still considered a highly speculative investment, necessitating caution regarding cash flow and positioning within a diversified portfolio.

consensus icon
Consensus
Volatile
valuation icon
Valuation
Undervalued
review icon
Similar
TRUL,TRUL
TOP PICK
Operates entirely in the US. Largest marijuana producer in the world by sales. Vertically integrated. Growing quickly organically and by acquisition. Regulatory tailwind. Democrats taking Senate increase likelihood of legislative reform. Great company, lots of growth runway. No dividend. (Analysts’ price target is $19.98)
BUY
It's the largest US MSO (multi-state operator) in several U.S. states. They've built up a small private company over two years, then went public. MSOs are capturing more attention and capital flows.
TOP PICK
Operates entirely in US, with 10x the market. Canadian red tape has made it difficult for regulated companies to take market share from black market. Whereas US market is undersupplied. Vertical integration and geographic diversity are part of its strategy. Good management. No dividend. (Analysts’ price target is $17.47)
HOLD
He finds it fascinating that cannabis is still illegal in the US, but is deemed essential during the pandemic. He thinks this will lead to relaxed regulations in the future. The company generates increasing revenue and positive cash flow -- only a handful of US cannabis companies do. He thinks it will be a dominant player in years to come in the space.
BUY
CURELF-N vs. CL-X. He really made a focus on the US for cannabis. He thinks the US MSOs have a tremendous amount of room to go. CURELF-N is one of the leaders. CL-X just did a deal in California, which is one of the biggest markets out there. He likes both of them. They are both leaders.
Showing 31 to 35 of 35 entries